- Home
- ATNF vs HSCS Comparison
ATNF vs HSCS Comparison
Compare ATNF & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- HSCS
- Stock Information
- Founded
- ATNF 2016
- HSCS 2007
- Country
- ATNF United States
- HSCS United States
- Employees
- ATNF N/A
- HSCS N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- HSCS Medical Specialities
- Sector
- ATNF Health Care
- HSCS Health Care
- Exchange
- ATNF Nasdaq
- HSCS Nasdaq
- Market Cap
- ATNF 4.1M
- HSCS 3.8M
- IPO Year
- ATNF N/A
- HSCS 2022
- Fundamental
- Price
- ATNF $1.25
- HSCS $3.69
- Analyst Decision
- ATNF
- HSCS Strong Buy
- Analyst Count
- ATNF 0
- HSCS 2
- Target Price
- ATNF N/A
- HSCS $13.50
- AVG Volume (30 Days)
- ATNF 84.0K
- HSCS 19.2K
- Earning Date
- ATNF 03-04-2025
- HSCS 03-13-2025
- Dividend Yield
- ATNF N/A
- HSCS N/A
- EPS Growth
- ATNF N/A
- HSCS N/A
- EPS
- ATNF N/A
- HSCS N/A
- Revenue
- ATNF N/A
- HSCS $14,700.00
- Revenue This Year
- ATNF N/A
- HSCS $174.19
- Revenue Next Year
- ATNF $54.15
- HSCS $4,100.00
- P/E Ratio
- ATNF N/A
- HSCS N/A
- Revenue Growth
- ATNF N/A
- HSCS 151.28
- 52 Week Low
- ATNF $1.16
- HSCS $2.36
- 52 Week High
- ATNF $17.75
- HSCS $18.50
- Technical
- Relative Strength Index (RSI)
- ATNF 33.17
- HSCS 51.97
- Support Level
- ATNF $1.31
- HSCS $3.70
- Resistance Level
- ATNF $1.38
- HSCS $4.10
- Average True Range (ATR)
- ATNF 0.06
- HSCS 0.30
- MACD
- ATNF 0.01
- HSCS 0.03
- Stochastic Oscillator
- ATNF 0.00
- HSCS 59.00
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.